Bioreactor campaign management determines how many batches of each product a multi-product facility can deliver per year. The turnaround time between batches and the changeover procedure between products are the two largest sources of non-productive downtime in biologics manufacturing, yet most campaign plans are built on conservative assumptions that leave 10-20% of annual capacity on the table. This guide breaks down each component of turnaround time, explains how to validate a product changeover, and shows how scheduling strategies can recover that lost capacity.
What Is Campaign Manufacturing?
Campaign manufacturing is a production strategy where multiple consecutive batches of the same product are manufactured in the same equipment train before switching to a different product. It is the standard operating model for multi-product biologics facilities, from clinical CDMOs running 3-batch campaigns to commercial sites producing 15-20 batch campaigns per product per year.
A campaign has three distinct phases, each with its own time cost:
- Setup — equipment preparation, media hold, inoculation, and first-batch startup.
- Production — sequential batches with same-product turnaround (CIP, SIP, refill) between each batch.
- Changeover — validated cleaning, residue testing, line clearance, and preparation for the next product.
The ratio of production time to total campaign time (including setup and changeover) is the campaign utilization. For a 14-day fed-batch process in stainless steel bioreactors, a single-batch campaign has a utilization of roughly 75%, while a 10-batch campaign reaches 93%. Extending campaigns beyond 10 batches yields diminishing returns because changeover time is amortized across more batches, but inventory carrying costs increase linearly with campaign length.
| Term | Definition | Typical Duration |
|---|---|---|
| Same-product turnaround | CIP + SIP + integrity test + media fill between batches of the same product | 8-12 h (SS), 4-6 h (SUS) |
| Product changeover | Validated cleaning + residue testing + line clearance + QA release | 2-5 days |
| Campaign length | Number of consecutive batches of one product | 3-20 batches |
| Campaign utilization | Production time / total campaign time × 100% | 75-95% |
| MACO | Maximum allowable carryover of previous product residue | Calculated per product pair |
| Line clearance | Physical and documented verification that no previous-product material remains | 2-4 h |
Turnaround Time: Stainless Steel vs Single-Use
Stainless steel bioreactor turnaround between same-product batches typically takes 8-12 hours, dominated by CIP, SIP, and cool-down. Single-use systems eliminate CIP and SIP entirely, reducing turnaround to 4-6 hours for bag removal, installation, leak testing, and media fill. The difference compounds across a campaign: over 10 batches, stainless steel consumes 3.5-5 days in turnaround alone, while single-use needs only 1.5-2.5 days.
The stainless steel turnaround sequence follows a fixed order with minimal parallelization because each step must complete before the next begins:
- Drain and rinse — 1 h. Remove harvest residuals with WFI or purified water.
- CIP pre-wash — 0.5 h. Alkaline pre-rinse to remove gross protein soils.
- NaOH main wash — 1 h. 0.5 M NaOH at 65-80°C, the primary cleaning step.
- Intermediate rinse — 0.5 h. WFI rinse to conductivity < 5 μS/cm.
- Acid wash — 0.5 h. Phosphoric acid (0.5-1%) to remove mineral deposits.
- Final rinse — 0.5 h. WFI to conductivity and TOC acceptance criteria.
- SIP — 1 h. Steam sterilization at 121°C for 15-30 min hold, measured at the cold spot.
- Cool-down — 1 h. Cooling jacket water to bring the vessel to inoculation temperature.
- Integrity test — 0.5 h. Pressure hold test on all filters and connections.
- Media preparation and fill — 2 h. Media transfer from hold tank, pH and DO set-points.
Changeover Validation and Cleaning Carryover Limits
A product changeover requires validated proof that residues from the previous product have been reduced to safe levels before the next product can be manufactured. For biologics, this means demonstrating that active protein residues, cleaning agents, and microbial bioburden are all below defined acceptance criteria. The entire changeover adds 2-5 days on top of the standard turnaround.
The two regulatory approaches for setting cleaning acceptance limits are:
- 1/1000 dose criterion — The maximum carryover of Product A must not exceed 1/1000 of the minimum therapeutic dose of Product A in the maximum daily dose of Product B. This is the traditional approach.
- Health-based exposure limits (PDE/ADE) — Per EMA guidelines (2014) and the ISPE Risk-MaPP guide, the Permitted Daily Exposure (PDE) sets the acceptance limit based on toxicological data. Preferred for new facility validations as of 2026.
The MACO formula for the 1/1000 dose approach:
MACO Calculation
MACO = (TDDA × BSB) / (SF × MDDB)
- TDDA = Minimum therapeutic dose of Product A (mg)
- BSB = Minimum batch size of Product B (mg or mL)
- SF = Safety factor (typically 1000 for the 1/1000 criterion)
- MDDB = Maximum daily dose of Product B (mg or mL)
For a mAb facility switching from Product A (dose: 200 mg) to Product B (batch size: 10,000 L, max daily dose: 400 mg):
MACO = (200 mg × 10,000,000 mL) / (1000 × 400 mL) = 5,000 mg = 5 g
This 5 g must be distributed across all shared surfaces. If the total shared surface area is 25 m², the acceptance limit per swab area (25 cm²) is:
Limit = 5,000 mg / (25 × 10,000 cm²) × 25 cm² = 0.5 μg/cm²
Analytical methods for verifying cleaning include swab sampling with TOC analysis (acceptance: < 5 ppm carbon), rinse sample testing by HPLC or ELISA for product-specific residues, and endotoxin testing of final rinse water (< 0.25 EU/mL).
How Long Does a Bioreactor Turnaround Actually Take?
A same-product turnaround in stainless steel bioreactors takes 8-12 hours in practice, depending on vessel size, CIP circuit complexity, and SIP cold-spot mapping. A product changeover extends this to 2-5 days because of the additional cleaning verification steps. The table below gives realistic durations for each phase at commercial scale (2,000 L).
| Phase | Stainless Steel | Single-Use | Notes |
|---|---|---|---|
| Same-product turnaround | 8-12 h | 4-6 h | CIP/SIP eliminated in SUS |
| CIP cycle | 3-4 h | N/A | Alkaline + acid + rinses |
| SIP cycle | 1.5-2 h | N/A | Including heat-up and cool-down |
| Product changeover (cleaning) | 8-16 h | 1-2 h | SUS: bag disposal only |
| Changeover verification | 1-3 days | 4-8 h | Swab/rinse testing + lab turnaround |
| QA review and release | 0.5-1 day | 0.5-1 day | Documentation review, line clearance |
| Total changeover | 2-5 days | 1-2 days | Including all verification |
The largest variability sits in the analytical turnaround for swab and rinse samples. Facilities with in-house TOC analyzers and rapid HPLC methods can return results in 4-8 hours, while those sending samples to an external QC lab may wait 1-3 days. Investing in rapid analytical capability directly shortens changeover time.
Optimizing Campaign Length for Facility Utilization
Campaign length is the single most impactful variable for facility utilization. Longer campaigns reduce the fraction of time spent on changeover, but the improvement follows a diminishing-returns curve that flattens above 10 batches. The optimal campaign length depends on changeover duration, batch cycle time, demand volume, and the number of products sharing the facility.
The campaign utilization formula:
Utilization = N × Tbatch / (N × Tbatch + (N-1) × Tturnaround + Tchangeover)
Where N = number of batches, Tbatch = batch duration (e.g. 14 days for a fed-batch mAb process), Tturnaround = same-product turnaround time, and Tchangeover = full product changeover time.
For a stainless steel facility with 8.5-hour turnaround and 3-day changeover, increasing campaign length from 1 batch (75% utilization) to 5 batches (89%) recovers 14 percentage points, while going from 5 to 10 batches gains only 4 more points (93%). Single-use systems start higher at 82% for a single batch and reach 93% by 5 batches.
Multi-Product Scheduling Strategies
Three scheduling strategies determine how many batches a multi-product facility produces per year: sequential campaigns, staggered campaigns, and continuous integrated processing. Each trades scheduling complexity for throughput gains.
| Strategy | Description | Annual Batches (est.) | Downstream Utilization | Complexity |
|---|---|---|---|---|
| Sequential campaigns | All bioreactors run the same product; full changeover between products | 44-52 | 40-50% | Low |
| Staggered campaigns | Bioreactors staggered every 3-4 days; shared downstream runs continuously | 56-64 | 70-85% | Medium |
| Continuous integrated | Perfusion upstream + continuous chromatography; steady-state operation | Equivalent of 70-80 | 85-95% | High |
Sequential campaigns are the simplest: all bioreactors produce the same product, the downstream train processes one batch at a time, and a full changeover separates each product. Downstream utilization is low (40-50%) because the purification train sits idle while batches are growing.
Staggered campaigns offset bioreactor inoculations by the downstream processing time (typically 3-4 days) so that as one batch enters harvest, the previous batch is finishing polishing chromatography. This keeps the downstream train continuously loaded and increases annual output by 15-25%. The scheduling constraint is that all staggered bioreactors must run the same product to avoid cross-contamination in the shared downstream train.
Continuous integrated processing pairs perfusion bioreactors with continuous chromatography for steady-state operation. This eliminates the batch-to-batch turnaround concept entirely but requires significant capital investment and process development.
Worked Example: Annual Capacity of a 4 × 2,000 L Suite
Worked Example: Sequential vs Staggered Campaign Planning
Facility: 4 × 2,000 L stainless steel bioreactors, shared downstream train
Process: CHO fed-batch mAb, 14-day batch cycle, 5 g/L titer
Products: 3 products, equal demand
Operating days: 350 per year
Scenario A: Sequential campaigns (8-batch campaigns, 3 products)
- Batch cycle: 14 days + 0.35 day turnaround = 14.35 days per batch
- Campaign time: 8 × 14.35 = 114.8 days + 3-day changeover = 117.8 days
- Campaigns per year: 350 / 117.8 = 2.97 → 2 full campaigns per product
- Annual batches per bioreactor: 2 campaigns × 8 batches × 3 products / 3 = 16 batches
- Total across 4 bioreactors (sequential): 48 batches/year
- Annual output: 48 × 2,000 L × 5 g/L = 480 kg mAb
Scenario B: Staggered campaigns (bioreactors offset by 4 days)
- All 4 bioreactors staggered: new harvest every 3.5 days
- Effective batch cycle per slot: 14 days / 4 bioreactors = 3.5 days between harvests
- Annual batches: (350 days − 3 changeovers × 3 days) / 3.5 = 97.4 → approximately 60 batches/year (accounting for turnaround and realistic scheduling gaps)
- Annual output: 60 × 2,000 L × 5 g/L = 600 kg mAb
- Improvement: +25% output vs sequential
Fermentation Economics Calculator
Model the cost impact of different campaign strategies on your facility's annual COGS per gram.
Changeover Documentation and Regulatory Expectations
Regulatory agencies expect documented evidence that every product changeover follows a validated procedure. The changeover package typically includes six elements that must be complete before the first batch of a new campaign can begin.
- Completed batch records for the outgoing campaign (all batches reconciled and closed).
- Executed cleaning protocols with documented CIP cycle parameters (temperature, concentration, flow rate, contact time) for each vessel and process line.
- Cleaning verification results — swab samples, rinse samples, and visual inspection results, all below validated acceptance criteria.
- Equipment logbook entries documenting maintenance, calibration status, and any deviations during the outgoing campaign.
- Line clearance verification — physical check that no previous-product materials, labels, or documentation remain in the production area.
- QA approval — formal sign-off authorizing the start of the new campaign after review of all changeover documentation.
For facilities producing multiple biologics, the deviation and CAPA process must address changeover-related failures specifically, including incomplete cleaning, out-of-spec residue results, and scheduling errors that bring incompatible products into proximity.
Scale-Up Calculator
Size your bioreactors and plan seed train expansion for campaign manufacturing at different scales.
Frequently Asked Questions
What is bioreactor campaign manufacturing?
Campaign manufacturing is a production strategy where multiple consecutive batches of the same product are produced in the same equipment before switching to a different product. Campaign lengths typically range from 3 to 20 batches, and each campaign ends with a validated changeover procedure including cleaning, verification, and setup for the next product.
How long does a bioreactor turnaround take?
A stainless steel bioreactor turnaround (same-product, between batches) typically takes 8-12 hours including CIP, SIP, cool-down, integrity testing, and media fill. A product changeover adds 2-5 days for cleaning validation sampling, analytical testing, and documentation. Single-use bioreactors reduce within-campaign turnaround to 4-6 hours by eliminating CIP and SIP steps.
What is the MACO calculation for bioreactor changeover?
MACO (Maximum Allowable Carryover) is the maximum amount of residue from the previous product that can remain on shared equipment surfaces. For biologics, MACO is calculated as: MACO = (TDD of Product A × Minimum batch size of Product B) / (Safety factor × Maximum daily dose of Product B). The 1/1000 dose criterion and health-based exposure limits (PDE/ADE) per EMA guidelines are the two main approaches.
How do you optimize campaign length for multi-product facilities?
Optimal campaign length balances facility utilization against inventory holding costs and demand responsiveness. Longer campaigns (10-20 batches) maximize utilization by reducing the ratio of changeover downtime to productive time, but increase inventory carrying costs. Most multi-product mAb facilities settle on 5-10 batch campaigns, achieving 85-93% facility utilization.
Can you run multiple products simultaneously in the same facility?
Yes, using staggered scheduling where upstream and downstream operations for different products run in parallel. A 4-bioreactor suite can stagger harvests every 3-4 days, keeping the downstream train continuously loaded. The critical constraint is preventing cross-contamination through dedicated product-contact equipment, validated cleaning between products on shared equipment, and robust scheduling to avoid suite conflicts.
What documentation is required for a bioreactor changeover?
A validated changeover requires: completed batch records for the outgoing product, executed cleaning protocols with cleaning verification results (swab and rinse samples below acceptance criteria), equipment logbook entries, environmental monitoring data, line clearance verification, incoming product setup verification, and a formal changeover approval by quality assurance before the first batch of the new campaign can begin.
Related Tools
- Fermentation Economics Calculator — Model COGS impact of campaign length and turnaround time on annual manufacturing costs.
- Scale-Up Calculator — Size bioreactors and plan seed train expansion for multi-product facilities.
- Heat Transfer Calculator — Calculate SIP heat-up and cool-down times for stainless steel vessels.
References
- Lakhdar K., Zhou Y., Savery J., Titchener-Hooker N.J., Papageorgiou L.G. (2005). Medium term planning of biopharmaceutical manufacture using mathematical programming. Biotechnology Progress, 21(5), 1478-1489. doi:10.1021/bp0501571
- Siganporia C.C., Ghosh S., Daszkowski T., Papageorgiou L.G., Farid S.S. (2014). Capacity planning for batch and perfusion bioprocesses across multiple biopharmaceutical facilities. Biotechnology Progress, 30(3), 594-606. doi:10.1002/btpr.1860
- Pollock J., Coffman J., Ho S.V., Farid S.S. (2017). Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture. Biotechnology Progress, 33(4), 854-866. doi:10.1002/btpr.2492
- Kumar V., Shaik M.A. (2026). Revised long-term scheduling model for multi-stage biopharmaceutical processes. Mathematical and Computational Applications, 31(1), 32. doi:10.3390/mca31010032
- Xu S., Gavin J., Jiang R., Chen H. (2017). Bioreactor productivity and media cost comparison for different intensified cell culture processes. Biotechnology Progress, 33(4), 867-878. doi:10.1002/btpr.2415